Skip to main content
FinSpry Logo
FinSpry
BBOT logo
BBOT
(NASDAQ)
BridgeBio Oncology Therapeutics, Inc.
$8.91-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

BridgeBio Oncology Therapeutics, Inc. (BBOT) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for BridgeBio Oncology Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 9 professional research analysts

Consensus Rating

Buy
Based on 9 unique analysts
Medium Confidence∞:1 Buy/Sell

Average Price Target

$19.11
↑ 114.48% Upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest BBOT Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Google Biotechnology
TipRanks - Google
HoldInitiates
$10.00
PerPlexity Biotechnology
TipRanks - PerPlexity
HoldInitiates
$10.00
Laura Prendergast
Stifel Nicolaus
BuyMaintains
$23.00
OpenAI Biotechnology
TipRanks - OpenAI
HoldInitiates
$10.00
Robert Burns
HC Wainwright
Strong BuyMaintains
$27.00 → $29.00
Biren Amin
Piper Sandler
BuyMaintains
$21.00
Matthew Biegler
Oppenheimer
BuyReiterates
$22.00
Laura Prendergast
Stifel
Strong BuyInitiates
$23.00
Sean McCutcheon
Raymond James
BuyInitiates
$24.00

Frequently Asked Questions

What is the analyst consensus rating for BBOT?

The analyst consensus rating for BBOT is "Buy" based on 9 analyst recommendations.

What is the average price target for BBOT?

The average 12-month price target for BBOT is $19.11, representing an upside of 114.5% from the current price of $8.91.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.